Simplify Logo

Full-Time

Director – Facilities

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Hardware
Biotechnology

Compensation Overview

$215k - $228kAnnually

+ Equity Component

Senior, Expert

San Carlos, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Management
Customer Service
Requirements
  • BS in Engineering or similar technical-related degree.
  • 8+ years’ Facilities experience in the life sciences industry, biotech preferred.
  • 5+ years’ people-management experience.
  • Project management experience with office and lab builds; manufacturing a plus.
  • Expert-level proficiency with facilities and lab systems such as BMS, CMMS, ELN/LIMS.
  • Proficient, hands-on experience with biotech facility and laboratory instruments and equipment.
  • Relentless focus and passion around process improvements (efficiency and automation).
  • Fluent in Facilities-related statutory/regulatory requirements for a public life sciences company.
  • Proficiency developing and managing corporate EH&S programs.
  • Practical experience with system/equipment qualification plans and protocols.
  • Ability to thrive in a highly-dynamic and fluid environment where priorities may quickly change.
  • Excellent communication, customer service and relationship skills are an absolute must.
Responsibilities
  • Partner closely with the Director of Lab Operations to establish, monitor and maintain the labs and all lab equipment.
  • Support planning oversight for the installation of lab equipment.
  • Help cultivate a culture of compliance with job-appropriate policies, procedures and training.
  • Collaborate, develop and evolve a rolling 3-5 year strategic Facilities roadmap for Vaxcyte’s HQ and associated spaces.
  • Plan and co-lead relocations, expansions and redesign initiatives.
  • Oversee ongoing space planning and assignment move/add/change efforts.
  • Manage site functions as assigned.
  • Establish and maintain 24x7 on-call schedule, site lead roster and emergency call tree for Facilities team.
  • Help drive key processes and systems related to Facility operations to ensure they are integrated and monitored.
  • Maintain master calendar for required inspections, preventative maintenance, submissions, renewals, and (re)certifications via Facilities Computerized Maintenance Management System (CMMS). CMMS will be the master database for the general facilities including the Labs and lab equipment.
  • Establish and operationalize strategic relationships with key external partners.
  • Lead, coach and manage a high-performing Facilities team with a focus on career growth.
  • Help nurture and grow workplace engagement through creative Facilities solutions.
  • Liaise regularly with property managers, external agencies and key 3rd party partners.
  • Engage regularly with employees and business partners to forge relationships and build trust.
  • Operationalize and/or automate Facilities functions for improved consistency and efficiency.
  • Support the development of procedures that comply with appropriate cGxP and other statutory requirements.
  • Manage Vaxcyte HQ Facilities projects and serve as SME for cross-functional and enterprise initiatives.
  • Establish functional KPI’s and report regularly on performance against metric/measure targets.
  • Create a customer-centric Facilities support capability built upon solid process and technology.
  • Work with IT and business partners to identify, implement and evolve Facilities systems.
  • Partner closely with Finance to establish, monitor and maintain Facilities budgets.
  • Plan, oversee and track Facilities-related procurement; help optimize procurement process.
  • Serve as Facilities SME and point of contact during audits.
  • Assist with Vaxcyte’s emergency and continuity planning with ongoing table-top exercises.
  • Support troubleshooting and perform minor repairs in office and laboratory settings.
  • Member of Emergency Response Team.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to protect vulnerable populations from serious bacterial infections.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

53%

2 year growth

114%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.